Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western kenya who have uncomplicated malaria

J Infect Dis. 2008 Nov 15;198(10):1550-3. doi: 10.1086/592715.

Abstract

Sulfadoxine-pyrimethamine (SP) inhibits folate metabolism by the malaria parasite. We investigated the association between folate levels and SP failure in pregnant women. Data from a trial to assess the effect that folate supplementation has on SP failure in 467 pregnant women were analyzed. Plasma folate levels were determined at enrollment and at day 7. High baseline folate levels, high parasite densities, and age <20 years were risk factors for SP failure. High-dose (5 mg daily) folate supplementation or high folate levels at day 7 were independent risk factors. Therefore, pregnant women receiving SP should receive low-/moderate-dose folate supplementation.

Trial registration: http://www.clinicaltrials.gov identifier: NCT00130065.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Animals
  • Antimalarials / therapeutic use*
  • Dietary Supplements*
  • Drug Combinations
  • Female
  • Folic Acid / administration & dosage*
  • Folic Acid / blood*
  • Humans
  • Kenya
  • Malaria / drug therapy*
  • Pregnancy
  • Pregnancy Complications, Parasitic / drug therapy*
  • Pyrimethamine / therapeutic use*
  • Risk Factors
  • Sulfadoxine / therapeutic use*
  • Survival Analysis
  • Treatment Failure
  • Young Adult

Substances

  • Antimalarials
  • Drug Combinations
  • fanasil, pyrimethamine drug combination
  • Sulfadoxine
  • Folic Acid
  • Pyrimethamine

Associated data

  • ClinicalTrials.gov/NCT00130065